Specifications
- Purity
- ≥98% (NMR)
- Appearance
- White powder
- Identity
- 1H-NMR
Properties
- Solvents
- DMSO, ethanol, methanol, propylene, chloroform
- Melting Point
- 97-98°C (lit.)
Documentation
- Safety Data Sheet (SDS)
- CDX T0200 MSDS.pdf
Available from stock
Tamoxifen
- SKU
- T0200
Category: Antibiotics
- Synonyms
- (Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene, trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
- 10540-29-1
- CAS-Number
- C26H29NO
- Molecular Formula
- 371.51
- Molecular Weight
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
- Shipping
- AMBIENT
- Short Term Storage
- +4°C
- Long Term Storage
- +4°C
- Handling Advice
- Protect from light and moisture.
- Use / Stability
- Stable for at least 2 years after receipt when stored at +4°C.
- Hazard statements
- H350-H360-H362
- Precautionary statements
- P201-P263-P308+P313
- GHS Symbol
- GHS08
- Signal word
- Danger
- Transportation
- Not dangerous goods
- Description
- Selective estrogen receptor modulator (SERM) used as adjuvant therapy for estrogen-dependent breast cancer. Antagonist of ER action in breast tissue and breast cancer cells and ER agonist in bone, uterus, and the cardiovasculature system. This prodrug is metabolized by cytochrome P450 (CYP450) enzymes to the active metabolites N-desmethyl-TMX, 4-hydroxy-N-desmethyl-TMX (endoxifen) and 4-hydroxy-TMX (afimoxifene). N,N-Didesmethyl-4-hydroxytamoxifen (norendoxifen), another active metabolite has been found to act as a potent competitive aromatase inhibitor and may also be involved in its antiestrogenic activity. Binds microsomal antiestrogen binding sites, altering cholesterol esterification at therapeutic doses and impacting breast cancer cell differentiation, apoptosis, and autophagy. Protein kinase C (PKC) inhibitor and anti-angiogenetic factor.
- Smiles
- CN(CCOC1=CC=C(/C(C2=CC=CC=C2)=C(C3=CC=CC=C3)/CC)C=C1)C
- InChi Key
- NKANXQFJJICGDU-QPLCGJKRSA-N
- References
- K. B. Horwitz & W. L. McGuire, J. Biol. Chem. 253, 8185 (1978) , V.C. Jordan, et al., Cancer Treat. Rep. 64, 745 (1980) , C.A. O'Brian, et al., Cancer Res. 45, 2462 (1985) , K.J. Edwards, et al., J. Med. Chem. 35, 2753 (1992) , M. Clarke, et al., Lancet 351, 1451 (1998) , D.A. Tonetti & V.C. Jordan, Mol. Med. Today 2, 218 (1996) , J.M. Hall, et al., J. Biol. Chem. 276, 36869 (2001) , P. Thomas, et al., Endocrinol. 146, 624 (2005) , M.S. Singh, et al., Breast 20, 111 (2011) , P. de Medina, et al., Chem. Phys. Lip. 164, 432 (2011) , V.K. Todorova, et al., Cancer Chemother. Pharmacol. 67, 285 (2011)
- InChi
- InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-
Selective estrogen receptor modulator (SERM) used as adjuvant therapy for estrogen-dependent breast cancer. Antagonist of ER action in breast tissue and breast cancer cells and ER agonist in bone, uterus, and the cardiovasculature system. This prodrug is metabolized by cytochrome P450 (CYP450) enzymes to the active metabolites N-desmethyl-TMX, 4-hydroxy-N-desmethyl-TMX (endoxifen) and 4-hydroxy-TMX (afimoxifene). N,N-Didesmethyl-4-hydroxytamoxifen (norendoxifen), another active metabolite has been found to act as a potent competitive aromatase inhibitor and may also be involved in its antiestrogenic activity. Binds microsomal antiestrogen binding sites, altering cholesterol esterification at therapeutic doses and impacting breast cancer cell differentiation, apoptosis, and autophagy. Protein kinase C (PKC) inhibitor and anti-angiogenetic factor.
Additional information
| Synonyms | (Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene, trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine |
|---|---|
| Purity | ≥98% (NMR) |
| Appearance | White powder |
| CAS-Number | 10540-29-1 |
| Molecular Formula | C26H29NO |
| Molecular Weight | 371.51 |
| Identity | 1H-NMR |
| Solvents | DMSO, ethanol, methanol, propylene, chloroform |
| Melting Point | 97-98°C (lit.) |
| Smiles | CN(CCOC1=CC=C(/C(C2=CC=CC=C2)=C(C3=CC=CC=C3)/CC)C=C1)C |
| InChi Key | NKANXQFJJICGDU-QPLCGJKRSA-N |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | +4°C |
| Handling Advice | Protect from light and moisture. |
| Use / Stability | Stable for at least 2 years after receipt when stored at +4°C. |
| Hazard statements | H350-H360-H362 |
| Precautionary statements | P201-P263-P308+P313 |
| GHS Symbol | GHS08 |
| Signal word | Danger |
| Transportation | Not dangerous goods |
| References | K. B. Horwitz & W. L. McGuire, J. Biol. Chem. 253, 8185 (1978), V.C. Jordan, et al., Cancer Treat. Rep. 64, 745 (1980), C.A. O'Brian, et al., Cancer Res. 45, 2462 (1985), K.J. Edwards, et al., J. Med. Chem. 35, 2753 (1992), M. Clarke, et al., Lancet 351, 1451 (1998), D.A. Tonetti & V.C. Jordan, Mol. Med. Today 2, 218 (1996), J.M. Hall, et al., J. Biol. Chem. 276, 36869 (2001), P. Thomas, et al., Endocrinol. 146, 624 (2005), M.S. Singh, et al., Breast 20, 111 (2011), P. de Medina, et al., Chem. Phys. Lip. 164, 432 (2011), V.K. Todorova, et al., Cancer Chemother. Pharmacol. 67, 285 (2011) |
| InChi | InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25- |
| Quantity | 1 g, 5 g, Bulk |
